For example, integrin beta 4 (ITGB4), which is a constituent of the EGFR-EMT 5-gene prognostic signature, was identified as a potential candidate for blocking antibodies and as predictive marker for the response of advanced, metastasized HNSCC patients to Cetuximab [48]. This evidence concerns the gene ITGB4 and head and neck squamous cell carcinoma.